Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10664173 | 0.75 | LPAR3 (0.51) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL9711831 | 0.73 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL21764567 | 0.73 | LPAR3 (0.57) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL497151 | 0.72 | LPAR3 (0.71) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL15876073 | 0.72 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| Isopropyl Alcohol SCHEMBL27837425 | 0.71 | LPAR3 (0.64) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL3824229 | 0.70 | LPAR3 (0.63) | LPAR3LPAR2LPAR1PLA2G2A | |
| Phosphoric Acid SCHEMBL4949196 | 0.70 | LPAR3 (0.68) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL11806157 | 0.70 | LPAR3 (0.68) | LPAR3LPAR2LPAR1P2RY10 | |
| SCHEMBL150117 | 0.70 | LPAR3 (0.68) | LPAR3LPAR2LPAR1P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594976-A4 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS | PARKER HUGHES INST (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PARKER HUGHES INSTITUTE (US) | 2006-12-28 | — | — | US | disclosed |
| US-7144874-B2 | Aryl phosphate derivatives of d4T having activity against resistant HIV strains | PARKER HUGHES INSTITUTE (US) | 2006-12-05 | — | — | US | disclosed |
| US-7071176-B2 | Aryl phosphate derivatives of AZT having anti-HIV activity | PARKER HUGHES INSTITUTE (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277620-A1 | Aryl phosphate derivatives of d4T | PARKER HUGHES INSTITUTE (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1594976-A2 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS | Parker Hughes Institute (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050143339-A1 | Aryl phosphate derivatives of D4T with potent anti-viral activity | PARKER HUGHES INSTITUTE (US) | 2005-06-30 | — | — | US | disclosed |
| EP-1334108-B1 | ARYL PHOSPHATE DERIVATIVES OF d4T | PARKER HUGHES INST (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6825177-B2 | 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (D4T); EXTENDING THE ELIMINATION HALF-LIFE OF D4T METABOLITE IN A MAMMAL ADMINISTERING SAID DERIVATIVE; TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) | PARKER HUGHES INSTITUTE | 2004-11-30 | — | — | US | disclosed |
| EP-1334108-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T | Parker Hughes Institute (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6537975-B1 | Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent | PARKER HUGHES INSTITUTE | 2003-03-25 | — | — | US | disclosed |
| US-6528495-B1 | Para-bromo substitution on the aryl group shows markedly increased potency without undesirable levels of cytotoxic activity; inhibitors of HIV reverse transcriptase; phosphorus of the aryl phosphate is substituted with an amino acid | PARKER HUGHES INSTITUTE | 2003-03-04 | — | — | US | disclosed |
| US-6503890-B1 | Reverse transcriptase inhibitors | PARKER HUGHES INSTITUTE | 2003-01-07 | — | — | US | disclosed |
| US-20020137726-A1 | Aryl phosphate derivatives of D4T with potent anti-viral activity | PARKER HUGHES INSTITUTE | 2002-09-26 | — | — | US | disclosed |
| WO-2002038576-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T | PARKER HUGHES INSTITUTE (US) | 2002-05-16 | — | — | WO | disclosed |
| US-6350736-B1 | phenyl methoxyalaninyl phosphate derivatives of 2',3'-didehydro-2',3'-dideoxythymidine with an electron-withdrawing moiety, such as p-bromo, for enhanced hydrolysis, have increased potency without high cytotoxic activity; inhibitors of HIV reverse transcriptase; thymidine-kinase (TK)-deficient cells | PARKER HUGHES INSTITUTE | 2002-02-26 | — | — | US | disclosed |
| EP-1090018-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | Parker Hughes Institute (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6030957-A | INHIBITING HIV(HUMAN IMMUNODEFICIENCY VIRUS) REVERSE TRANSCIPTASE IN CELLS INFECTED WITH HIV BY ADMINISTERING TO INFECTED CELLS ARYLPHOSPHATE DERIVATIVE OF 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE | WAYNE HUGHES INSTITUTE (US) | 2000-02-29 | — | — | US | disclosed |
| WO-2000000501-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | LPAR3 2905/4885LPAR2 3640/4885LPAR1 3008/4885 |
| US-20050277620-A1 | Aryl phosphate derivatives of d4T | PNP, MTAP, TYMP | LPAR3 2948/4885LPAR2 2565/4885LPAR1 3045/4885 |
| US-20020137726-A1 | Aryl phosphate derivatives of D4T with potent anti-viral activity | TYMP, PNP, GART | LPAR3 2945/4885LPAR2 2720/4885LPAR1 2724/4885 |
| US-20060293285-A1 | Aryl Phosphate Derivatives of d4T | PNP, TYMP, APRT | LPAR3 3161/4885LPAR2 4006/4885LPAR1 3512/4885 |
| US-20050143339-A1 | Aryl phosphate derivatives of D4T with potent anti-viral activity | TYMP, PNP, APRT | LPAR3 2809/4885LPAR2 2442/4885LPAR1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.